

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934
(Amendment No.2 and Amendment No.4)*

QUESTCOR PHARMACEUTICALS INC.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

232808105

(CUSIP Number)

Joseph J. Giunta, Esq.
Skadden, Arps, Slate, Meagher & Flom LLP
300 South Grand Avenue
Los Angeles, CA 90071
(213) 687-5000

(Name, Address and Telephone Number of Person Authorized to
Receive Notices and Communications)

January 31, 2003

(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of ss.240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box .

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

CUSIP No. 232808105

1 NAME OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS

Claudio Cavazza

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a)
(b)

3 SEC USE ONLY

4 SOURCE OF FUNDS

PF, AF

5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED
PURSUANT TO ITEMS 2(d) OR 2(e)

6 CITIZENSHIP OR PLACE OF ORGANIZATION

Italy

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	7	SOLE VOTING POWER 2,656,781
	8	SHARED VOTING POWER 10,698,712
	9	SOLE DISPOSITIVE POWER 2,656,781
	10	SHARED DISPOSITIVE POWER 10,698,712

11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

13,355,493

12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

32.11%

14 TYPE OF REPORTING PERSON

IN

SCHEDULE 13D

CUSIP No. 232808105

1 NAME OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS

Paolo Cavazza

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a)
(b)

3 SEC USE ONLY

4 SOURCE OF FUNDS

PF, AF

5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED
PURSUANT TO ITEMS 2(d) OR 2(e)

6 CITIZENSHIP OR PLACE OF ORGANIZATION

Italy

NUMBER OF	7	SOLE VOTING POWER
SHARES		2,656,782
BENEFICIALLY	8	SHARED VOTING POWER
OWNED BY		11,147,812
EACH	9	SOLE DISPOSITIVE POWER
REPORTING		2,656,782
PERSON WITH	10	SHARED DISPOSITIVE POWER
		11,147,812

11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

13,804,594

12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
CERTAIN SHARES

13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

33.19%

14 TYPE OF REPORTING PERSON

IN

SCHEDULE 13D

CUSIP No. 232808105

1 NAME OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS

Sigma-Tau Finanziaria SpA

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a)
(b)

3 SEC USE ONLY

4 SOURCE OF FUNDS

AF

5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED
PURSUANT TO ITEMS 2(d) OR 2(e)

6 CITIZENSHIP OR PLACE OF ORGANIZATION

Italy

NUMBER OF	7	SOLE VOTING POWER
SHARES		0

BENEFICIALLY	8	SHARED VOTING POWER
OWNED BY		10,698,712

EACH	9	SOLE DISPOSITIVE POWER
REPORTING		0

PERSON WITH	10	SHARED DISPOSITIVE POWER
		10,698,712

11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

10,698,712

12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
CERTAIN SHARES

13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

26.29%

14 TYPE OF REPORTING PERSON

CO

SCHEDULE 13D

 CUSIP No. 232808105

1 NAME OF REPORTING PERSONS
 I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS

Sigma-Tau International S.A.

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a)
 (b)

3 SEC USE ONLY

4 SOURCE OF FUNDS

WC

5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED
 PURSUANT TO ITEMS 2(d) OR 2(e)

6 CITIZENSHIP OR PLACE OF ORGANIZATION

Luxembourg

	7	SOLE VOTING POWER
NUMBER OF		0
SHARES		
BENEFICIALLY	8	SHARED VOTING POWER
OWNED BY		10,698,712
EACH		
REPORTING	9	SOLE DISPOSITIVE POWER
PERSON WITH		0
	10	SHARED DISPOSITIVE POWER
		10,698,712

11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

10,698,712

12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
 CERTAIN SHARES

13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

26.29%

14 TYPE OF REPORTING PERSON

CO

SCHEDULE 13D

CUSIP No. 232808105

1 NAME OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS

Defiante Farmaceutica L.D.A.

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a)
(b)

3 SEC USE ONLY

4 SOURCE OF FUNDS

WC

5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED
PURSUANT TO ITEMS 2(d) OR 2(e)

6 CITIZENSHIP OR PLACE OF ORGANIZATION

Portugal

7 SOLE VOTING POWER
NUMBER OF SHARES 0

8 SHARED VOTING POWER
BENEFICIALLY OWNED BY EACH 2,025,315

9 SOLE DISPOSITIVE POWER
REPORTING PERSON WITH 0

10 SHARED DISPOSITIVE POWER
2,025,315

11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

2,025,315

12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
CERTAIN SHARES

13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

4.98%

14 TYPE OF REPORTING PERSON

CO

Amendment No. 2 and
Amendment No. 4 to
Statement on Schedule 13D

This Amendment No. 2 (the "Amendment No. 2") amends the Statement on Schedule 13D filed with the Securities and Exchange Commission ("SEC") on March 25, 2002 (the "Sigma/Defiante Schedule 13D"), as amended, relating to shares of the common stock, no par value (the "Common Shares"), of Questcor Pharmaceuticals Inc., a California corporation ("Questcor"). This Amendment No. 4 (the "Amendment No. 4" and, together with the Amendment No. 2, this "Statement") amends the Statement on Schedule 13D, filed with the SEC on August 7, 2001 (the "Cavazza/Sigma Schedule 13D" and, together with the Sigma/Defiante Schedule 13D, the "Schedule 13Ds"), as amended, relating to the Common Shares of Questcor. Pursuant to Rule 13d-2 of Regulation 13D-G promulgated under the Securities Exchange Act of 1934, as amended, this Amendment No. 2 is being filed on behalf of Sigma-Tau Finanziaria SpA, an Italian corporation ("Sigma Tau") and Defiante Farmaceutica L.D.A., a Portuguese corporation ("Defiante") (formerly known as Defiante Farmaceutica Unipessoal L.D.A.), and this Amendment No. 4 is being filed on behalf of Sigma-Tau International S.A., a Luxembourg corporation ("Sigma Tau International") (formerly known as Sigma-Tau Finance Holding S.A.), Mr. Claudio Cavazza ("Mr. C. Cavazza") and Mr. Paolo Cavazza ("Mr. P. Cavazza" and, together with Mr. C. Cavazza, Sigma Tau International, Defiante and Sigma Tau, the "Reporting Persons").

Item 4. Purpose of the Transaction.

Item 4 of the Schedule 13Ds are hereby amended as follows:

The Reporting Persons originally acquired the shares reported herein to gain an equity investment interest in Questcor. The Reporting Persons evaluate on an ongoing basis Questcor's financial condition, business operations and prospects. To enable them to better make such evaluations, Mr. Mauro Bove ("Mr. Bove"), on behalf of the Reporting Persons, had a telephonic conversation on January 16, 2003 with Mr. Charles Casamento ("Mr. Casamento"), Chairman, President and CEO of Questcor, requesting representation on the Questcor Board of Directors (the "Board"). Specifically, Mr. Bove requested an increase in the number of directors of Questcor by two, such directors to be nominated by the Reporting Persons and elected by the Board as soon as possible (the "Request"). Mr. Casamento informed Mr. Bove that he would discuss the Request with the Board during the next meeting of the Board to be held on January 24, 2003. Upon conclusion of the meeting, Mr. Casamento would advise Mr. Bove of the Board's decision.

Mr. Casamento sent a letter, dated as of January 28, 2003, to Mr. Bove (the "Questcor Letter"). A copy of the Questcor Letter is attached hereto as Exhibit 2 and is incorporated by reference.

In response to the Questcor Letter, Mr. Bove, on behalf of the Reporting Persons, has sent a letter, dated as of January 31, 2003, to Mr. Casamento and the Board (the "Sigma Tau Letter"). A copy of the Sigma Tau Letter is attached hereto as Exhibit 3 and is incorporated by reference.

Except as set forth in this Item 4, the Reporting Persons have no present plans or proposals that relate to or that would result in any of the actions specified in clauses (a) through (j) of Item 4 of Schedule 13D of the Act.

Item 7. Material to be Filed as Exhibits.

EXHIBIT 1 - Joint Filing Agreement dated January 17, 2003 by and between the Reporting Persons(1).

EXHIBIT 2 - The Questcor Letter.

EXHIBIT 3 - The Sigma Tau Letter.

1 Incorporated by reference to Exhibit 1 of Amendment No. 1 and Amendment No. 3 to the Statement on Schedule 13D, filed with the SEC on January 17,

2003, relating to the Common Shares of Questcor.

Signatures

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement with respect to Claudio Cavazza is true, complete and correct.

Dated: February 3, 2003

CLAUDIO CAVAZZA

By: /s/ CLAUDIO CAVAZZA

Name: Claudio Cavazza

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement with respect to Paolo Cavazza is true, complete and correct.

Dated: February 3, 2003

PAOLO CAVAZZA

By: /s/ PAOLO CAVAZZA

Name: Paolo Cavazza

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement with respect to Sigma-Tau Finanziaria SpA is true, complete and correct.

Dated: February 3, 2003

SIGMA-TAU FINANZIARIA SPA

By: /s/ MARIO ARTALI

Name: Mario Artali
Title: Managing Director

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement with respect to Sigma-Tau International S.A. is true, complete and correct.

Dated: February 3, 2003

SIGMA-TAU INTERNATIONAL S.A.

By: /s/ ANTONIO NICOLAI

Name: Antonio Nicolai
Title: Director

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement with respect to Defiante Farmaceutica L.D.A. is true, complete and correct.

Dated: February 3, 2003

By: /s/ RAFFAELE SANGUIGNI

Name: Raffaele Sanguigni
Title: Director

The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative (other than an executive officer or general partner of the filing person), evidence of the representative's authority to sign on behalf of such person shall be filed with the statement: provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001)

January 28, 2003

Mauro Bove
Sigma Tau Finanziaria S.p.A.
Via Sudafrica n.20
00144 - Rome
Italy

Dear Mauro:

I am writing this letter in response to our telephone conversation on January 16, 2003 in which you requested, on behalf of Sigma Tau Finanziaria S.p.A. and its affiliates ("Sigma Tau"), that Questcor Pharmaceuticals, Inc. ("Questcor") increase the size of its Board of Directors (the "Board") by two, with such directors to be nominated by Sigma Tau and elected by the Board as soon as possible. As I promised you, I presented your request to the Board at its regularly scheduled meeting held on January 24, 2003. The Board discussed your request at such meeting and is currently considering the request.

In order for the Board to complete its review of your request, the Board has determined that it needs the following information with respect to each of the two persons Sigma Tau would like to nominate to the Board: such person's name; such person's resume (including such person's experience on boards of directors of United States public companies generally, and in the pharmaceutical and biotech industries specifically); and such person's relationship and/or affiliation with Sigma Tau. These are all items of information that Questcor is required to provide to its shareholders regarding its directors in its annual proxy statement.

Additionally, the Board has expressed an interest in having one or more of its members meet and talk with Sigma Tau's two prospective nominees in person. Jon Saxe, a member of the Board, will be in London at the end of this week and is willing to make himself available to meet with these two prospective nominees at a mutually agreeable time and location. Please let me know if it would be possible to arrange such a meeting with Mr. Saxe while he is in London or, alternatively, to arrange a meeting at some other mutually agreeable time and location in the near future.

I look forward to receiving your response to the above inquiries at your earliest convenience.

Sincerely,

/s/ CHARLES CASAMENTO

Charles J. Casamento

January 31, 2003

Charles Casamento
Chairman, President and CEO
Questcor Pharmaceuticals, Inc.
3260 Whipple Road
Union City, CA 94587

Dear Charles,

Thank you for your letter dated January 28, 2003. You have asked for information related to the two persons that we would like to nominate. Fortunately, members of the Board of Directors, including Mr. Saxe, are already well acquainted with our nominees, Paolo Cavazza and myself. Per your request, our resumes are attached and our affiliation with Sigma Tau is fully disclosed in our Schedule 13D on file with the Securities Exchange Commission.

While neither Mr. Cavazza nor I have served on public company boards in the United States, through our investments in, and interactions with, numerous public companies, as well as our extensive experience in private company boards and our affiliates' extensive holdings in Questcor, we feel confident in our ability to represent the interests of shareholders on the Questcor Board of Directors. If necessary, we would be happy to arrange a telephonic meeting to discuss our qualifications further. In any event, please advise us of your final decision with respect to our request for Board representation no later than February 5, 2003.

Regards,

/s/ MAURO BOVE

Mauro Bove

cc: Board of Directors of Questcor Pharmaceuticals, Inc.